Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience

Marker Therapeutics, Inc.

Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.
Over 20 years experience; previously interim CMO at multiple biotechs, VP Clinical Development at Geron, Senior Medical Director at Genentech.
She is a transplant physician with expertise in AML and lymphoma, aligning with Marker's prioritized clinical programs.
Dr. Stuart will lead clinical strategy for MT-401 in AML and MT-601 in non-Hodgkin lymphoma and pancreatic cancer.
CEO Juan Vera cited her deep industry experience and clinical background as key to advancing pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.